Measuring Eating Behaviors After Bariatric Surgery
Official title: Direct Measurement of Ingestive Behaviour in Relation to Sex Differences and Gastrointestinal Hormone Levels in Patients After Metabolic and Bariatric Surgery
Run by University of Zurich · NCT06538948 · Data updated 2026-11-12
This study is trying to see how bariatric surgery changes drinking habits in patients and how those changes relate to weight loss and other health outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 420 (estimated) |
| Sponsor | University of Zurich Academic / other |
| Locations | 2 sites (Männedorf, Canton of Zurich and 1 other locations) |
| Status | Recruiting |
| Started | February 13, 2024 |
| Main results expected | August 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | May 18, 2026 |
| Trial ID | NCT06538948 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a BMI of 35 or higher planning to undergo bariatric surgery, as well as external controls with varying BMI levels.
✕Probably not a fit
Patients with a history of previous bariatric surgeries, smoking, diabetes, or polycystic ovary syndrome may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates how bariatric surgery affects eating behaviors by using a device called the 'drinkometer' to directly measure changes in drinking behavior in patients after procedures like Sleeve Gastrectomy and Roux-en-Y gastric bypass. The study aims to explore the relationship between these behaviors, sex differences, and gut hormone levels, providing a more accurate understanding of post-operative outcomes. By analyzing these factors, the research seeks to correlate changes in ingestive behavior with weight loss and other clinical outcomes over time.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of eating behaviors post-surgery, potentially enhancing patient outcomes and weight loss strategies.
How similar studies have gone: While studies on ingestive behavior exist, this approach using direct measurement with the drinkometer is relatively novel and has not been extensively tested in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 year * BMI ≥ 35 kg/m2 for patients with planned RYGB or SG operation * BMI ≥ 30 kg/m2 for external controls affected by obesity but no planned RYGB or SG within the next 12 months, and * BMI ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2 for controls without obesity. Exclusion Criteria: * history of previous bariatric operations and/ or revisional surgery (e.g., alteration of limb lengths after primary RYGB), * smoking, * established diagnosis of type 1 or 2 diabetes mellitus, and * polycystic ovary syndrome (PCOS).
Where it's running
-
Hospital Männedorf
Männedorf, Canton of Zurich, Switzerland Recruiting -
University Hospital Zurich, Department of Surgery and Transplantation
Zurich, Canton of Zurich, Switzerland Recruiting
Study contacts
- Principal investigator: Marco Bueter, MD, DPhil — University of Zurich
- Study coordinator: Marco Bueter, MD, DPhil
- Email: m.bueter@spitalmaennedorf.ch
- Phone: +41442558895
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.